Search - tctmd.com

Displaying 441 - 460 of 473

Sort: Relevancy | Date

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

L.A. McKeown

March 09, 2017

News Daily News

Less Acute MI, More HF: European Task Force Shifts Support for ‘Overhyped’ Cell Therapy Research

Yael L. Maxwell

February 22, 2017

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

News Daily News

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

Michael O'Riordan

December 01, 2016

News Conference News AHA 2016

Interatrial Shunt Device Shows Sustained Improvement in Heart Failure Patients With Preserved EF

Shelley Wood

November 16, 2016

News Conference News AHA 2016

Intravenous Iron, Not Oral, Improves Functional Capacity in HF Patients

Michael O'Riordan

November 16, 2016

News Daily News

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Yael L. Maxwell

August 29, 2016

News Conference News ESC 2016

ICDs Do Not Reduce Mortality in Patients With HF Not Caused by Coronary Artery Disease: DANISH

Michael O'Riordan

August 28, 2016

News Conference News ESC 2016

Another Meeting, Another Mesenchymal Stem Cell Study (or Two), With Mixed Results

Shelley Wood

August 28, 2016

News Daily News

Las Estatinas Minimizan pero No Eliminan el Exceso de Riesgo de Enfermedad Coronaria y Muerte en la Hipercolesterolemia Familiar

Todd Neale

July 12, 2016

News Daily News

美国和欧洲的心衰指南提倡使用两个新疗法

L.A. McKeown

May 24, 2016

News Daily News

US and European Heart Failure Guidelines Advocate Use of Two New Therapies

L.A. McKeown

May 24, 2016

News Opinion Editor's Corner

ACC 2016: HOPE for Primary Prevention, TAVR in Moderate-Risk Patients, Deferred Stenting in STEMI, and More

Shelley Wood

March 28, 2016

News Daily News

¿Estatinas para el Manejo de la Calcificación Aórtica? Un Estudio de Imágenes Debate sobre el Papel de las LBD en la Enfermedad de la Válvula Aórtica

Shelley Wood

December 16, 2015

News Industry News

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

October 27, 2015

News Conference News TCT 2015

Companies With Innovative Technologies Compete in TCT Shark Tank

October 13, 2015

News Conference News TCT 2015

Despite Setbacks, Research Into Myocardial Salvage Continues

October 12, 2015

News Industry News

Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are Maintained After 12 Months

September 28, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

Advertisement

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

Less Acute MI, More HF: European Task Force Shifts Support for ‘Overhyped’ Cell Therapy Research

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

Interatrial Shunt Device Shows Sustained Improvement in Heart Failure Patients With Preserved EF

Intravenous Iron, Not Oral, Improves Functional Capacity in HF Patients

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

ICDs Do Not Reduce Mortality in Patients With HF Not Caused by Coronary Artery Disease: DANISH

Another Meeting, Another Mesenchymal Stem Cell Study (or Two), With Mixed Results

Las Estatinas Minimizan pero No Eliminan el Exceso de Riesgo de Enfermedad Coronaria y Muerte en la Hipercolesterolemia Familiar

美国和欧洲的心衰指南提倡使用两个新疗法

US and European Heart Failure Guidelines Advocate Use of Two New Therapies

ACC 2016: HOPE for Primary Prevention, TAVR in Moderate-Risk Patients, Deferred Stenting in STEMI, and More

¿Estatinas para el Manejo de la Calcificación Aórtica? Un Estudio de Imágenes Debate sobre el Papel de las LBD en la Enfermedad de la Válvula Aórtica

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

Companies With Innovative Technologies Compete in TCT Shark Tank

Despite Setbacks, Research Into Myocardial Salvage Continues

Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are Maintained After 12 Months

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content